Cresco Labs Inc. (CL) Earnings Call Transcripts
Cresco Labs Inc.'s Latest Earnings Call - Q2 FY2026
In the second quarter of 2026, Colgate-Palmolive (CL:US) reported strong financial results, with revenue reaching $4.2 billion, representing a 6% increase year-over-year. Earnings per share (EPS) came in at $0.75, exceeding expectations by $0.05. Management raised their gross margin guidance to flat for the year, indicating confidence in their operational strategies despite ongoing inflationary pressures. The company continues to focus on innovation and market share growth, particularly in emerging markets, while addressing challenges in the U.S. market.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $4.2B (beat) |
| EPS | $0.75 (beat) |
| Gross Margin | 40.5% (positive) |
| Free Cash Flow | $1.4B (positive) |
| Organic Sales Growth | 2.6% (inline) |
| Advertising Spend | 14% of sales (neutral) |
Guidance from management
Management raised their gross margin guidance to flat for the year, indicating confidence in their operational strategies despite ongoing inflationary pressures. They maintained a cautious outlook for organic sales growth in the second half, reflecting uncertainties in consumer behavior.
What analysts pressed on
Analysts expressed concerns about the disparity between retail sales tracking data and reported results, questioning whether unmeasured channels are affecting visibility. There were also inquiries regarding the sustainability of growth in emerging markets and the effectiveness of advertising spend in the current environment.
Main topics on the call
- Strong Revenue Growth — Colgate-Palmolive achieved revenue of $4.2 billion, up 6% year-over-year, driven by strong performance in emerging markets. CEO Noel Wallace stated, "Our sales growth was led by emerging markets, which were up mid-single...
- Gross Margin Improvement — The company reported a gross margin increase of 100 basis points, attributed to effective pricing strategies and revenue growth management. CFO Stan Sutula noted, "We expect the good to peak in the back half of this year...
- U.S. Market Challenges — Management expressed dissatisfaction with U.S. performance, indicating a need for strategic changes. Wallace mentioned, "We will work to maintain this global momentum while driving improvement in the U.S. where we were n...
- Emerging Market Strength — Emerging markets showed resilience, with organic sales growth driven by premium products. Wallace highlighted, "We're seeing a lot of our focus on premiumization in that market," particularly in India and Brazil.
Read the full Cresco Labs Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Cresco Labs Inc.
Cresco Labs Inc. (CL) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on CNSX and is based in CA. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 98 calls on record spanning January 31, 2020 to August 6, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 98 Cresco Labs Inc. earnings call transcripts on record, spanning January 31, 2020 to August 6, 2026. Based on this history, Cresco Labs Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CL
- Exchange
- CNSX
- Country
- CA
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 98
- First call
- January 31, 2020
- Most recent
- August 6, 2026
- Reporting cadence
- quarterly